Geschäftskunden Kundenprogramme
Vor Ort
Merkzettel Warenkorb
Produktbild: Phenotypic Oncology PET

Phenotypic Oncology PET An Instructional Casebook

Fr. 137.00

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

18.10.2022

Verlag

Springer

Seitenzahl

339

Maße (L/B/H)

24.1/16/2.4 cm

Gewicht

771 g

Auflage

1st ed. 2022

Sprache

Englisch

ISBN

978-3-031-09736-2

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

18.10.2022

Verlag

Springer

Seitenzahl

339

Maße (L/B/H)

24.1/16/2.4 cm

Gewicht

771 g

Auflage

1st ed. 2022

Sprache

Englisch

ISBN

978-3-031-09736-2

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Phenotypic Oncology PET

  • Double pulmonary nodules.- Nodular sclerosing Hodgkin’s lymphoma.- Transformation in non-Hodgkin’s lymphoma.- Metabolic phenotypes in different neoplasms.- Marrow involvement in non-Hodgkin’s lymphoma.- Hip pain in lymphoma.- Prostate cancer specific PET agent with rising PSA.- Brain tumor evaluation.- Metabolic phenotypes in slowly growing lung cancers.- Metabolic phenotypes in lung metastasis from colon cancer.- PET and bone scan in non-small cell lung cancer (NSCLC).- Neuroendocrine cancer of ileum.- Coexisting different PET tumor phenotypes.- COVID vaccination and lung nodules.- COVID vaccination and tumor phenotypes.- Breast and ovarian uptake.- Rising PSA in radical prostatectomy for prostate cancer.- Concurrent lung and brain metastatic cancer.- Tumor phenotypes in metastatic prostate cancer.- Metastatic recurrent melanoma.- Post-prostatectomy for prostate cancer with rising PSA.- Left adrenal mass.- Cutaneous T-cell lymphoma.- Active myeloma versus Schmorl’s node.- Small cell lung cancer.- Synchronous PEComa and lung adenocarcinoma.- Breast cancer after immunochemotherapy.- Squamous cell lung cancer.- Lymphoma and breast cancer.- Prostate cancer.- Neurofibromatosis and cerebellar encephalomalacia.- Mucinous Colonic Adenocarcinoma.- Poorly differentiated gastric cancer with signet-ring cell features.- Granulomatosis disease involving lung, lymph nodes, and multiple bones.- Lung nodules in esophageal cancer.- Squamous cell cancer (SCC) of neck.- Metastatic prostate adenocarcinoma.- Mesothelioma.- Recurrent papillary thyroid carcinoma.- Newly diagnosed prostate adenocarcinoma.- Alveolar rhabdomyosarcoma with a favorable response to chemoradiation.- CNS post-transplant lymphoproliferative disease.- Solitary plasmacytoma.- Parotid oncocytic carcinoma.- Pelvic sarcoma with IVC metastatic thrombus.- Diffuse muscle uptake and vigorous exercise.- Post-excision residual urothelial carcinoma.- Phenotypic pattern of Erdheim-Chester disease (ECD).- Different metabolicphenotypes in renal clear cell cancer and cervix cancer.- Bladder adenocarcinoma with chemoresistance.- Wax-and-wane metabolic activities of low-grade lymphoma.- Reactive adenopathy in treated classic Hodgkin’s lymphoma.- Chemo-refractory diffuse large B cell lymphoma (DLBCL).- Primary cutaneous DLBCL, leg type (PC-DLBCL LT).- Primary pulmonary MALT lymphoma.- Concurrent low-grade follicular lymphoma (LG FL) and DLBCL.- Primary bone lymphoma (PBL).- Lymphomatoid granulomatosis (LYG) variant of DLBCL.- Secondary central nervous system lymphoma (SCNSL).- Complete discordant PET in pathologically diagnosed low grade lymphoma.- Transplant-related B-cell lymphoma.- Bone lesions in primary breast lymphoma.- Recurrent gastrointestinal stromal tumor (GIST) with necrosis.- Peritoneal mesothelioma.- Cutaneous Kaposi sarcoma.- FDG-avid and non-FDG-avid multiple myeloma (MM).- Advanced pancreatic cancer with abdominopelvic carcinomatosis.- Advanced breast cancer with extensive bone metastases.- Concurrent lung cancer and endocervix cancer.- Inflammatory breast cancer.- Recurrent high-grade urothelial carcinoma.- Primary thyroid lymphoma (PTL).- High-grade tonsillar large B-cell lymphoma.- Phenotypic pattern of primary renal DLBCL with double expressor.- Recurrent primary colonic lymphoma (PCL).- Maxillofacial extra nodal marginal zone malignant B-cell lymphoma.- Primary dural lymphoma with leptomeningeal involvement.- Primary CNS lymphoma (PCNSL).- Primary gastric lymphoma.- Residual primary prostate lymphoma.- PET SuperScan.- Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH).- Metastatic ovarian carcinoma.- Metastatic prostate cancer or neuroendocrine tumor?.- Metastatic thyroid carcinoma.- Primary invasive ductal breast cancer or metastatic neuroendocrine cancer?.- Atypical oligo-metastasis of malignant melanoma.- Dual-time PET CT evaluation of lung nodules.- Phenotypic pattern of combined large cell neuroendocrine cancer and SCC.- Primary pulmonary amyloidosis.- Advanced follicular dentritic cell sarcoma.- Oligometastatic prostate cancer.- Bulky primary mediastinal non-Hodgkin’s lymphoma.- Pulmonary sarcoid or recurrent lung adenocarcinoma?.- Oligo- or multiple bone metastases in newly diagnosed prostate cancer.- Reactive lymph nodes and granulomas associated with breast implant rupture.- Metabolic phenotypes of anaplastic thyroid carcinoma and metastases.- Male breast carcinoma.- Advanced HCC featured by IVC/right atrium tumor thrombus.- Phenotypes of lung cancer and pulmonary lymphangitic carcinomatosis.